Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05TBQ
|
||||
| Former ID |
DIB000829
|
||||
| Drug Name |
SAR408701
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 1/2 | [524831] | ||
| Target and Pathway | |||||
| Target(s) | Carcinoembryonic antigen-related cell adhesion molecule 5 | Target Info | [524831], [531635] | ||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| References | |||||
| Ref 524831 | ClinicalTrials.gov (NCT02187848) Evaluation of SAR408701 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | ||||
| Ref 531635 | Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.